Robotics, automation, active electrode arrays, and new devices for cochlear implantation: A contemporary review.

Cochlear implant Image-guided procedure Insertion tool Minimally invasive Neuronavigation Robotics

Journal

Hearing research
ISSN: 1878-5891
Titre abrégé: Hear Res
Pays: Netherlands
ID NLM: 7900445

Informations de publication

Date de publication:
02 2022
Historique:
received: 22 02 2021
revised: 16 12 2021
accepted: 23 12 2021
pubmed: 4 1 2022
medline: 15 3 2022
entrez: 3 1 2022
Statut: ppublish

Résumé

In the last two decades, cochlear implant surgery has evolved into a minimally invasive, hearing preservation surgical technique. The devices used during surgery have benefited from technological advances that have allowed modification and possible improvement of the surgical technique. Robotics has recently gained popularity in otology as an effective tool to overcome the surgeon's limitations such as tremor, drift and accurate force control feedback in laboratory testing. Cochlear implantation benefits from robotic assistance in several steps during the surgical procedure: (i) during the approach to the middle ear by automated mastoidectomy and posterior tympanotomy or through a tunnel from the postauricular skin to the middle ear (i.e. direct cochlear access); (ii) a minimally invasive cochleostomy by a robot-assisted drilling tool; (iii) alignment of the correct insertion axis on the basal cochlear turn; (iv) insertion of the electrode array with a motorized insertion tool. In recent years, the development of bone-attached parallel robots and image-guided surgical robotic systems has allowed the first successful cochlear implantation procedures in patients via a single hole drilled tunnel. Several other robotic systems, new materials, sensing technologies applied to the electrodes, and smart devices have been developed, tested in experimental models and finally some have been used in patients with the aim of reducing trauma in cochleostomy, and permitting slow and more accurate insertion of the electrodes. Despite the promising results in laboratory tests in terms of minimal invasiveness, reduced trauma and better hearing preservation, so far, no clinical benefits on residual hearing preservation or better speech performance have been demonstrated. Before these devices can become the standard approach for cochlear implantation, several points still need to be addressed, primarily cost and duration of the procedure. One can hope that improvement in the cost/benefit ratio will expand the technology to every cochlear implantation procedure. Laboratory research and clinical studies on patients should continue with the aim of making intracochlear implant insertion an atraumatic and reversible gesture for total preservation of the inner ear structure and physiology.

Identifiants

pubmed: 34979455
pii: S0378-5955(21)00259-8
doi: 10.1016/j.heares.2021.108425
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

108425

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All of the Authors work for or collaborate with the laboratory where the RobOtol® system has been designed and developed. OS and YN are currently consultant and scientific advisor respectively of Collin (Bagneux, France), commercial partner in the RobOtol project. This study was supported by Foundation pour l'Audition (laboratory starting grant ida-2020).

Auteurs

Daniele De Seta (D)

Inserm/Institut Pasteur, Institut de l'Audition, Technologie et Thérapie Génique de la Surdité, Paris, France; San Giovanni-Addolorata Hospital, Unit of Otolaryngology, Rome, Italy. Electronic address: daniele_deseta@yahoo.it.

Hannah Daoudi (H)

Inserm/Institut Pasteur, Institut de l'Audition, Technologie et Thérapie Génique de la Surdité, Paris, France; Sorbonne Université/AP-HP, GHU Pitié-Salpêtrière, DMU ChIR, Service ORL, GRC Robotique et Innovation Chirurgicale, Paris, France.

Renato Torres (R)

Inserm/Institut Pasteur, Institut de l'Audition, Technologie et Thérapie Génique de la Surdité, Paris, France; Sorbonne Université/AP-HP, GHU Pitié-Salpêtrière, DMU ChIR, Service ORL, GRC Robotique et Innovation Chirurgicale, Paris, France; Universidad Nacional de San Agustin de Arequipa, Facultad de Medicina, Departamento de Ciencias Fisiologicas, Av. Alcides Carrión 04000, Arequipa, Peru.

Evelyne Ferrary (E)

Inserm/Institut Pasteur, Institut de l'Audition, Technologie et Thérapie Génique de la Surdité, Paris, France.

Olivier Sterkers (O)

Inserm/Institut Pasteur, Institut de l'Audition, Technologie et Thérapie Génique de la Surdité, Paris, France; San Giovanni-Addolorata Hospital, Unit of Otolaryngology, Rome, Italy.

Yann Nguyen (Y)

Inserm/Institut Pasteur, Institut de l'Audition, Technologie et Thérapie Génique de la Surdité, Paris, France; Sorbonne Université/AP-HP, GHU Pitié-Salpêtrière, DMU ChIR, Service ORL, GRC Robotique et Innovation Chirurgicale, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH